• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

ALL-HEART: No Benefit of Allopurinol in Ischemic Heart Disease ALL-HEART: No Benefit of Allopurinol in Ischemic Heart Disease
Allopurinol failed to affect a composite of nonfatal MI, nonfatal stroke, or CV death, in a randomized trial that was ' definitively neutral ' in patients with heart disease but no gout.Medscape Medical News
Source: Medscape Internal Medicine Headlines - August 28, 2022 Category: Internal Medicine Tags: Cardiology News Source Type: news

Can I use DOAC in a patient with renal disease?
Case A 76-year-old man is diagnosed with non-valvular atrial fibrillation. His comorbid conditions are hypertension, diabetes complicated by neuropathy, and chronic kidney disease stage 3. His current medications include metformin, lisinopril, gabapentin, and aspirin. His most recent laboratories showed a creatinine 1.8, creatinine clearance (CrCl) 35 mL/min, hemoglobin 11g/dL, and international normalized ratio 1.0. His congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, and sex (CHADSVASc) score is 4. Which medication should we use to prevent stroke in this patient?  Brief overview of the is...
Source: The Hospitalist - February 3, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Renal & Genitourinary Source Type: research

Cardiovascular Disease in Gout and the  Protective Effect of Treatments Including Urate-Lowering Therapy
AbstractCardiovascular disease affects more than 90 million Americans. Recent studies support an increased cardiovascular disease risk in inflammatory conditions, such as gout. Increased serum urate levels, or hyperuricemia, are a precursor to gout. Data from meta-analyses have shown hyperuricemia to be linked to hypertension and coronary heart disease. Similarly, gout has been associated with an increased risk of myocardial infarction, cerebrovascular accidents, and death from cardiovascular disease in randomized clinical trials. Urate-lowering therapy reduces serum urate and may decrease systemic inflammation, generation...
Source: Drugs - March 12, 2019 Category: Drugs & Pharmacology Source Type: research

Serum uric acid is associated with better executive function in men but not in women: Baseline assessment of the ELSA-Brasil study.
CONCLUSION: In a middle-aged subset population, SUA is associated with better performance on an executive function test in men, but not in women in the ELSA-Brasil cohort study. PMID: 28300627 [PubMed - as supplied by publisher]
Source: Experimental Gerontology - March 10, 2017 Category: Geriatrics Authors: Baena CP, Suemoto CK, Barreto S, Lotufo P, Benseñor I Tags: Exp Gerontol Source Type: research

Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study
Introduction Ischaemic heart disease (IHD) is one of the most common causes of death in the UK and treatment of patients with IHD costs the National Health System (NHS) billions of pounds each year. Allopurinol is a xanthine oxidase inhibitor used to prevent gout that also has several positive effects on the cardiovascular system. The ALL-HEART study aims to determine whether allopurinol improves cardiovascular outcomes in patients with IHD. Methods and analysis The ALL-HEART study is a multicentre, controlled, prospective, randomised, open-label blinded end point (PROBE) trial of allopurinol (up to 600 mg daily) ver...
Source: BMJ Open - September 7, 2016 Category: Journals (General) Authors: Mackenzie, I. S., Ford, I., Walker, A., Hawkey, C., Begg, A., Avery, A., Taggar, J., Wei, L., Struthers, A. D., MacDonald, T. M., on behalf of the ALL-HEART study group Tags: Open access, Cardiovascular medicine, Pharmacology and therapeutics Protocol Source Type: research

Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities.
Abstract Stroke is the second leading cause of death, after ischemic heart disease, and accounts for 9% of deaths worldwide. According to the World Health Organization [WHO], 15 million people suffer stroke worldwide each year. Of these, more than 6 million die and another 5 million are permanently disabled. Reactive oxygen species [ROS] have been implicated in brain injury after ischemic stroke. There is evidence that a rapid increase in the production of ROS immediately after acute ischemic stroke rapidly overwhelm antioxidant defences, causing further tissue damage. These ROS can damage cellular macromolecules ...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2013 Category: Drugs & Pharmacology Authors: Rodrigo R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Merchak A, Feuerhake W Tags: CNS Neurol Disord Drug Targets Source Type: research